{"denoms":[{"counts":[{"groupId":"BG000","value":"35"}],"units":"Participants"}],"groups":[{"description":"Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4\n\nbortezomib: Bortezomib 1.3 mg/m2 days 1, 8, 15, 22\n\ndexamethasone: Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23\n\nmelphalan: Melphalan 9 mg/m2/day days 1-4\n\nmicroarray analysis: ≤28 days prior to enrollment\n\nflow cytometry: Day 1 of cycles 6, 12, 18 and at end of study.\n\nlaboratory biomarker analysis: ≤28 days prior to enrollment\n\nquality-of-life assessment: Start of each cycle","id":"BG000","title":"Melphalan, Dexamethasone, Bortezomib,"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"47","upperLimit":"83","value":"64"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"35"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}